1. Market Research
  2. > Healthcare
  3. > Blood Supply, Tissue Banking and Transplantation Market Trends
  4. > Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile

Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company which develops and commercializes Intercept Blood System for blood safety. The company has rights of Intercept for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion. It markets its product in the US, Europe, Russia, the Middle East and selected countries of other regions of the world for the treatment of both platelets and plasma for transfusions and it is also being developed for the treatment of red blood cells. Cerus is headquartered in Concord, California, the US.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy:

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 9
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cerus Corporation, Medical Equipment, Deal Details 11
Partnerships 11
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Cerus Enters Into Agreement With CSL 18
Equity Offering 19
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus Prices Public Offering of Shares for USD70 Million 20
Cerus Completes Public Offering Of Shares For US$40.3 Million 22
Cerus Completes Underwritten Public Offering Of US$21 Million 24
Cerus Corporation - Key Competitors 26
Key Employees 27
Locations And Subsidiaries 28
Head Office 28
Other Locations and Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Aug 04, 2016: Cerus Reports Second Quarter 2016 Results 29
May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results 31
Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results 33
Nov 05, 2015: Cerus Reports Third Quarter 2015 Results 35
Aug 06, 2015: Cerus Reports Second Quarter 2015 Results 37
May 05, 2015: Cerus Reports First Quarter 2015 Results 39
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results 41
Corporate Communications 43
Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation's Chief Commercial Officer 43
Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region 44
Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation's New Chief Medical Officer 45
Product News 46
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 46
Mar 15, 2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA's Revised Guidance Document on Bacterial Safety Standards for Platelets 47
Mar 09, 2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology 48
Feb 09, 2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma 49
Jan 14, 2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease 50
Jan 05, 2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma 51
Dec 10, 2015: Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma 52
Dec 07, 2015: Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma 53
Nov 02, 2015: Cerus Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma 54
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components 55
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 56
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden's Largest Blood Product Supplier 57
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System 58
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 59
Product Approvals 60
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma 60
Clinical Trials 61
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets 61
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint 62
Other Significant Developments 63
Oct 10, 2016: Cerus Announces that Hemolife Fundación Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System 63
Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma 64
Oct 21, 2015: Cerus Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits 66
Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68


List of Tables
Cerus Corporation, Medical Equipment, Key Facts, 2015 1
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Deals By Market, 2010 to YTD 2016 9
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016 10
Cerus Terminates Licensing Agreement With BioOne 11
Cerus Enters into Agreement with Haemonetics 12
Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan 13
Cerus Enters into Co-Marketing Agreement with Biomedica Foscama 14
Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma 15
Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma 16
Cerus Enters Into Distribution Agreement With Ilex Biotech 17
Cerus Enters Into Agreement With CSL 18
Cerus Plans to Raise USD70 Million in Public Offering of Shares 19
Cerus Prices Public Offering of Shares for USD70 Million 20
Cerus Completes Public Offering Of Shares For US$40.3 Million 22
Cerus Completes Underwritten Public Offering Of US$21 Million 24
Cerus Corporation, Key Competitors 26
Cerus Corporation, Key Employees 27
Cerus Corporation, Subsidiaries 28


List of Figures
Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 2016 1
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 2016 6
Cerus Corporation, Medical Equipment, Deals by Type, 2010 to YTD 2016 7
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 2016 8
Cerus Corporation, Medical Equipment, Deals by Market, 2010 to YTD 2016 9

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cord Blood America, Inc. (CBAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cord Blood America, Inc. (CBAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • August 2016
  • by Global Data

Summary Cord Blood America, Inc. (CBAI) is a pharmaceutical company that offers stem cell storage services. The company provides cord blood and cord tissue stem cell services. It collects, tests, processes ...

Blood Cell Storage, Inc. - Medical Equipment - Deals and Alliances Profile

Blood Cell Storage, Inc. - Medical Equipment - Deals and Alliances Profile

  • $ 250
  • Company report
  • October 2016
  • by Global Data

Summary Blood Cell Storage, Inc. (BCSI) is a medical device company that develops bio-medical technology products. The company’s products comprise IVF safe sens, platelets ph safe and nucleic acid extraction ...

New York Blood Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile

New York Blood Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • September 2016
  • by Global Data

Summary New York Blood Center (NYBC) is a healthcare organization which collects and distributes blood and blood products. The organization provides blood and stem cell products and related medical services ...

Haemonetics Corporation (usa)

February 2016 $ 1900

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.